Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,820 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy.
Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi K, Homma S, Kishi K; Investigators Group for Lung Cancer and IIP. Miyamoto A, et al. Among authors: nakagawa k. Sci Rep. 2024 May 3;14(1):10162. doi: 10.1038/s41598-024-60833-w. Sci Rep. 2024. PMID: 38702426 Free PMC article.
[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].
Nishiwaki Y, Yano S, Tamura T, Nakagawa K, Kudoh S, Horai T, Noda K, Takata I, Watanabe K, Saka H, Takeda K, Imamura F, Matsui K, Katakami N, Yokoyama A, Sawa Y, Takada M, Kiura K, Sugiura T, Fukuoka M, Uchida H. Nishiwaki Y, et al. Among authors: nakagawa k. Gan To Kagaku Ryoho. 2004 Apr;31(4):567-73. Gan To Kagaku Ryoho. 2004. PMID: 15114701 Clinical Trial. Japanese.
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K, Matsui K, Negoro S, Nakagawa K, Fukuoka M. Yoshimura N, et al. Among authors: nakagawa k. Lung Cancer. 2006 Mar;51(3):363-8. doi: 10.1016/j.lungcan.2005.10.006. Epub 2005 Dec 20. Lung Cancer. 2006. PMID: 16364494 Clinical Trial.
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M; Japan Thoracic Radiology Group; Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F. Kudoh S, et al. Among authors: nakagawa k. Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57. doi: 10.1164/rccm.200710-1501OC. Epub 2008 Mar 12. Am J Respir Crit Care Med. 2008. PMID: 18337594
Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.
Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M. Ohe Y, et al. Among authors: nakagawa k. Clin Cancer Res. 2008 Jul 1;14(13):4206-12. doi: 10.1158/1078-0432.CCR-07-5143. Clin Cancer Res. 2008. PMID: 18594001 Clinical Trial.
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Inoue A, Tomii K, Harada M, Masuda N, Jiang H, Itoh Y, Ichinose Y, Saijo N, Fukuoka M. Maruyama R, et al. Among authors: nakagawa k. J Clin Oncol. 2008 Sep 10;26(26):4244-52. doi: 10.1200/JCO.2007.15.0185. J Clin Oncol. 2008. PMID: 18779611 Clinical Trial.
4,820 results